Kymera Therapeutics, Inc., a limited liability company, was incorporated under the laws of the State of Delaware on May 25, 2017. The company is a biopharmaceutical company focused on the discovery and development of novel small molecule therapies that selectively degrade disease-causing proteins using the body's own natural protein degradation system. The company has a proprietary targeted protein degradation platform called Pegasus, which is able to discover highly selective small molecule protein degradation agents with strong activity on systemic disease-causing proteins. The company believes that its small molecule protein degraders have significant advantages over existing therapies, and can treat large areas of the human genome that were previously inaccessible to traditional therapies. The company focuses on biological pathways that have been clinically validated but whose key biological nodes/proteins have not been drug-targeted or whose drug targeting is not effective.